MGMT and glioblastoma: Although there may be discriminative imaging characteristics, our 18F-FDG-PET-based radiomics signature can predict the MGMT promoter methylation status regardless of the WHO grade (e.g., in lower grade gliomas and glioblastomas) or pathological information (e.g., in astrocytomas and oligodendrogliomas), suggesting the capability of noninvasive prediction without previous knowledge based on tumor samples.